Thermosome

Thermosome

Intravascular drug release. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
AUD13—19m (Dealroom.co estimates Apr 2016.)
Company register number HRB 189433 (München)
Planegg Bavaria (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2017201820192020202120222023
Revenues<1m<1m<1m<1m<1m<1m<1m
% growth-11483 %233 %(89 %)-89 %-

Source: Dealroom estimates

  • Edit

Recent News about Thermosome

Edit
More about Thermosomeinfo icon
Edit

Thermosome is a biotechnology company focused on developing advanced drug candidates using its proprietary drug delivery technology. This technology leverages a novel Mechanism of Action known as intravascular drug release, which is designed to treat localized diseases, particularly locally advanced solid tumors, where traditional systemic drugs fall short. The company's primary market is the oncology sector, targeting neoadjuvant treatment concepts. Thermosome's business model revolves around research and development of these specialized therapeutics, aiming to create significant value for patients by improving drug efficacy and minimizing systemic side effects. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of their developed drug candidates.

Keywords: biotechnology, drug delivery, intravascular release, oncology, localized treatment, solid tumors, neoadjuvant therapy, proprietary technology, R&D, therapeutics.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.